Head to Head Survey: Lifecore Biomedical (NASDAQ:LFCR) versus vTv Therapeutics (NASDAQ:VTVT)

Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) and vTv Therapeutics (NASDAQ:VTVT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Lifecore Biomedical and vTv Therapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lifecore Biomedical $128.87 million 1.88 -$70.51 million ($1.86) -3.44
vTv Therapeutics $1.02 million 69.74 -$26.97 million ($0.92) -19.28

vTv Therapeutics has lower revenue, but higher earnings than Lifecore Biomedical. vTv Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Lifecore Biomedical has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.

Institutional and Insider Ownership

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Lifecore Biomedical and vTv Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lifecore Biomedical -56.80% N/A -29.53%
vTv Therapeutics N/A -10.15% -8.65%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lifecore Biomedical and vTv Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifecore Biomedical 2 3 0 0 1.60
vTv Therapeutics 1 1 6 1 2.78

Lifecore Biomedical presently has a consensus price target of $6.50, indicating a potential upside of 1.48%. vTv Therapeutics has a consensus price target of $55.83, indicating a potential upside of 214.73%. Given vTv Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than Lifecore Biomedical.

Summary

vTv Therapeutics beats Lifecore Biomedical on 9 of the 15 factors compared between the two stocks.

About Lifecore Biomedical

(Get Free Report)

Lifecore Biomedical, Inc. is a contract development and manufacturing organization (CDMO) focused on sterile injectable pharmaceutical products. The company works with customers on product development, formulation, analytical testing, regulatory support and commercial-scale manufacturing, including fill-finish services. Lifecore also develops and manufactures hyaluronic acid, a biopolymer used in medical products and other applications. Its capabilities support products in areas such as ophthalmology and orthopedics, as well as pharmaceutical and veterinary uses.

About vTv Therapeutics

(Get Free Report)

vTv Therapeutics is a U.S. clinical-stage biopharmaceutical company that discovers and develops small-molecule medicines for serious diseases. Its research has focused on metabolic conditions and other areas of significant medical need. The company’s candidates have included cadisegliatin, formerly known as TTP399, an oral glucokinase activator studied as an addition to insulin therapy for people with type 1 diabetes, and azeliragon, an investigational compound studied for Alzheimer’s disease. These are development-stage products, not established commercial medicines.

Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.